牛磺熊去氧膽酸 TUDCA
C 2 U 1
適應症與證據等級
法規與權威立場 (L4)
L4a · US FDA
立場:cautious
TUDCA is a US Food and Drug Administration-approved hydrophilic bile acid for the treatment of certain cholestatic liver diseases
來源 ↗ L4b · EU EFSA
立場:against
L4c · UK NHS
立場:not_addressed
TUDCA will usually be administered as an add-on treatment to riluzole although it may be administered alone for patients who are unable to tolerate riluzole.
來源 ↗ L4d · TW TFDA / 衛福部
立場:against
含URSO(Ursodeoxycholic acid,去氧熊膽酸)成分之單方製劑統一為醫師處方用藥,適應症統一為「膽固醇系膽結石之溶解、原發性膽道肝硬化(primary biliary cirrhosis, PBC)之肝功能改善」。
來源 ↗ L4e · WHO
立場:not_addressed
Ursodoxicoltaurine is the International Nonproprietary Name (INN) for tauroursodeoxycholic acid (TUDCA), the taurine conjugate of ursodeoxycholic acid.
來源 ↗ 市場與行銷 (L10)
L10a · TW Market Channels
TUDCA 牛磺熊去氧膽酸,500 毫克,60 粒膠囊
L10b · TW Legal Identity (TFDA)
食品未取得衛生福利部健康食品查驗登記許可證,而宣稱為「健康食品」或具健康食品之保健功效者,則依違反健康食品管理法,移送法辦。
L10c · TW Community (PTT/Dcard/Mobile01)